1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS
- 30 April 2012
- journal article
- abstracts
- Published by Elsevier in Journal of Hepatology
- Vol. 56, S469-S470
- https://doi.org/10.1016/s0168-8278(12)61198-2